FDA issues guidance on drug sample delivery requirements during pandemic

The Food and Drug Administration does not intend to object to a manufacturer or authorized distributor delivering prescription drug samples directly to licensed practitioners or their patients at their homes during the COVID-19 emergency when requested by the practitioner in accordance with requirements, according to guidance released yesterday.

FDA also does not intend to take action during the emergency against a manufacturer or authorized distributor that accepts alternatives to a signature to verify delivery and receipt of drug samples if the receipt complies with other requirements, the guidance states.